Tecovirimat
- Generic Name
- Tecovirimat
- Brand Names
- Tpoxx, Tecovirimat SIGA
- Drug Type
- Small Molecule
- Chemical Formula
- C19H15F3N2O3
- CAS Number
- 869572-92-9
- Unique Ingredient Identifier
- F925RR824R
- Background
The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon. Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. It is effective against all orthopoxviruses, including vac...
- Indication
Tecovirimat is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg. The efficacy of tecovirimat may be reduced in immunocompromised patients. In Europe, it is also indicated to treat complications due to replication of the vaccini...
- Associated Conditions
- Complication of Smallpox Vaccination, Cow pox, Monkeypox, Variola Major (Smallpox)
- Associated Therapies
- -
Assessment of the Efficacy and Safety of Tecovirimat in Patients with Monkeypox Virus Disease
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 150
- Registration Number
- NCT05597735
- Locations
- 🇨ðŸ‡
Pr Alexandra Calmy, Geneva, Switzerland
🇦🇷Fundación Huésped, Ciudad Autonoma de Buenos Aires, Argentina
🇧🇷Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
Tecovirimat in Non-hospitalized Patients With Monkeypox
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Marina Klein
- Target Recruit Count
- 120
- Registration Number
- NCT05534165
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦St. Paul's Hospital, BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 467
- Registration Number
- NCT04971109
- Locations
- 🇺🇸
Midwest Clinical Research Center, Dayton, Ohio, United States
🇺🇸Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸Meridian Clinical Research, Omaha, Nebraska, United States
Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 Days With JYNNEOS
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 100
- Registration Number
- NCT04957485
- Locations
- 🇺🇸
Meridian Clinical Research, Omaha, Nebraska, United States
🇺🇸Aventiv Research Inc, Columbus, Ohio, United States
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 44
- Registration Number
- NCT04485039
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 34
- Registration Number
- NCT04392739
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 449
- Registration Number
- NCT02474589
- Locations
- 🇺🇸
Paradigm Research, San Diego, California, United States
🇺🇸Sundance Clinical Research LLC, Saint Louis, Missouri, United States
🇺🇸Center for Pharmaceutical Research, Kansas City, Missouri, United States
Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure
Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 30
- Registration Number
- NCT00431951
- Locations
- 🇺🇸
Orlando Clinical Research, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.